{
  "docId": "019de075-c3df-7648-ab3f-403a3e018886",
  "docSlug": "132267474e075f06292187997a008f90",
  "documentTitle": "OmniAb | Investor Presentation Deck | 35 slides",
  "authorId": "omniab",
  "authorName": "OmniAb",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 35,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "market_sizing",
  "function": "size_opportunity",
  "density": "overcrowded",
  "nDataPoints": 7,
  "notes": "The slide uses a combination of bullet points, a comparison table, and a bar chart to build a market opportunity case.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c3df-7648-ab3f-403a3e018886/5",
  "deckHref": "/decks/019de075-c3df-7648-ab3f-403a3e018886",
  "deckJsonHref": "/decks/019de075-c3df-7648-ab3f-403a3e018886.json",
  "deckAnchorHref": "/decks/019de075-c3df-7648-ab3f-403a3e018886#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.15,
        "x": 0.44,
        "y": 0.58
      },
      "kind": "callout",
      "text": "Historical success rates for antibodies are significantly higher than small molecules",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "55a8bd1d-d6c8-45e8-ae03-4daf55bc9db2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.35,
        "x": 0.62,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Acceleration of Regulatory Approvals (FDA and EMA) showing growth from Pre-2000 to 2011-2020",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "21a0ff86-440d-4b0e-93cc-ad0a52266bce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.5,
        "x": 0.06,
        "y": 0.33
      },
      "kind": "list",
      "text": "$279B in antibody sales by 2025 (up from ~$238B in 2022); 51 blockbuster antibodies in 2022; 5 best-selling antibodies had ~$75B of sales in 2022",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f831c10f-03bb-4285-ad92-ca6e60200e5f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.04,
        "y": 0.92
      },
      "kind": "source-note",
      "text": "Sources: Clarivate Analytics Cortellis database. Tables of approved mAbs and antibodies in review available at: https://www.antibodysociety.org/resources/approved-antibodies/ (1) Defined as composite success rate of clinical development from Phase I trials to Approval, data from 2011-2020. Source: BIO | QLS Advisors | Informa Feb 2021 Report.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "28f5f2b9-18ec-4dd6-870d-247a11d4137a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.04,
        "y": 0.63
      },
      "kind": "table",
      "text": "Type of Drug: Small Molecules (7.5%), Antibodies (12.1%)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7ff78610-e26c-4d89-8e63-6f0b2264eed9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.92,
        "x": 0.04,
        "y": 0.13
      },
      "kind": "title",
      "text": "HIGHER CLINICAL SUCCESS RATES FOR ANTIBODY MEDICINES DRIVE OUR INDUSTRY'S NEED FOR DISCOVERY TECHNOLOGY",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c08151af-67d3-48d2-8c23-1eb2341ba8e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.45,
        "x": 0.04,
        "y": 0.04
      },
      "kind": "title",
      "text": "Antibodies and Industry Demand",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "63c875a6-c5b6-4a0d-9691-b706684b29b9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "bb519486-acfe-4d74-8a3d-a0f875a1936c",
      "evidence": "The slide uses a bar chart to show acceleration of regulatory approvals.",
      "confidence": 0.5
    }
  ],
  "frameworks": [
    {
      "name": "market-sizing",
      "slug": null,
      "matchId": "672b7f68-f848-48ab-8ad8-9bb64daa24d7",
      "evidence": "Quantifies market growth and success rates to justify industry demand.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [
    {
      "to": 5,
      "from": 5,
      "beatId": "061a0e1e-38e7-4ce5-9380-b4900aefece6",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The document presents the need for discovery technology in the biotech industry.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 35,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1674fffb-efec-427e-b437-66fc0c0fd01e",
      "evidence": "The document presents the potential consequences of not investing in effective discovery technology.",
      "position": 0,
      "objective": "Highlight the importance of investing in OmniAb's technology to drive growth and success in the biotech industry.",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}